A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Bookmark
Active drug More information Moderate burden on patient More information Started >3 years ago More information

Trial Details

Sponsor: PMV Pharmaceuticals, Inc (industry)

Phase: 1/2

Start date: Oct. 29, 2020

Planned enrollment: 230

Trial ID: NCT04585750
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: rezatapopt (PC14586)

TrialFetch AI Analysis

Goal: Evaluate the safety, dosing, pharmacokinetics, and antitumor activity of rezatapopt, alone or with pembrolizumab, in TP53 Y220C–mutant advanced solid tumors. The enrolling phase 2 portion focuses on monotherapy efficacy.

Patients: Patients with locally advanced or metastatic solid tumors harboring TP53 Y220C, ECOG performance status 0–1, progression after at least one prior anticancer regimen, and adequate organ function. Phase 2 requires RECIST-measurable disease and excludes tumors with a KRAS single-nucleotide variant. Enrollment generally begins at age 18, with ages 12–17 permitted after safety review approval.

Design: Open-label, multicenter, nonrandomized dose-escalation and expansion study without a control arm. Phase 1 monotherapy and phase 1b combination enrollment are complete; phase 2 monotherapy enrollment remains open in ovarian, lung, breast, endometrial, and other solid-tumor cohorts.

Treatments: Phase 2 participants receive rezatapopt 2,000 mg orally once daily with food. Earlier cohorts evaluated escalating daily doses alone or with pembrolizumab 200 mg IV every three weeks, followed by combination expansion in PD-(L)1–naive and relapsed/refractory patients. Rezatapopt is an investigational small molecule that selectively binds and stabilizes Y220C-mutant p53 to restore tumor-suppressor activity. In a published phase 1 study, the response rate was 20% across doses; a phase 2 ovarian-cancer conference abstract reported a 44.4% investigator-assessed response rate among 72 evaluable patients. These single-arm findings do not establish comparative benefit.

Outcomes: The phase 2 primary measure is independently reviewed RECIST v1.1 overall response rate, including evaluation in the ovarian cohort and across cohorts. Phase 1/1b primary measures include dose-limiting toxicities, adverse events, maximum tolerated dose, and recommended dose. Additional measures include response duration, disease control, progression-free and overall survival, pharmacokinetics, safety, and phase 2 quality of life.

Burden on patient: Moderate to high. Daily oral treatment and repeated response scans require ongoing visits; pharmacokinetic blood sampling adds procedures, particularly during dose escalation. Combination participants also need pembrolizumab infusions every three weeks. The provided details do not specify mandatory biopsies or an exact visit schedule.

Last updated: Sep 2026

Eligibility More information

Caution: ClinicalTrials.gov appears to have newer eligibility criteria than the version saved here. Review the current criteria in ClinicalTrials.gov.

chevron Show Criteria

Sites (76)

Sort by distance to:
Clear

Chris O'Brien Lifehouse Hospital

Camperdown, New South Wales, Australia

No email / No phone

Status: Recruiting

Mater Cancer Care Centre

South Brisbane, Queensland, Australia

No email / No phone

Status: Recruiting

Flinders Medical Center

Bedford Park, South Australia, Australia

No email / No phone

Status: Recruiting

Monash Medical Centre

Clayton, Victoria, Australia

No email / No phone

Status: Recruiting

Linear Clinical Research

Nedlands, Western Australia, Australia

No email / No phone

Status: Recruiting

CHU de Nîmes

Nîmes, 30900, France

No email / No phone

Status: Recruiting

Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer

Lyon, France

No email / No phone

Status: Recruiting

Institute Cancer De Lorraine

Vandœuvre-lès-Nancy, 54519, France

No email / No phone

Status: Recruiting

ICANS - Institut de cancérologie Strasbourg Europe

Strasbourg, Bas-Rhin, France

No email / No phone

Status: Recruiting

Institut Bergonie

Bordeaux, Gironde, France

No email / No phone

Status: Recruiting

Institut Claudius Regaud

Toulouse, Haute-Garonne, France

No email / No phone

Status: Recruiting

EDOG Institut de Cancerologie de l'Ouest

Saint-Herblain, Loire-Atlantique, France

No email / No phone

Status: Recruiting

Centre Jean Perrin

Clermont-Ferrand, Puy-de-Dôme, France

No email / No phone

Status: Recruiting

Institut Gustave Roussy

Villejuif, Val-de-Marne, France

No email / No phone

Status: Recruiting

Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg

Heidelberg, Baden-Wurttemberg, Germany

No email / No phone

Status: Recruiting

Universitätsklinikum Augsburg

Augsburg, Bavaria, Germany

No email / No phone

Status: Recruiting

Asklepios Klinik Altona

Hamburg, Free and Hanseatic City of Hamburg, Germany

No email / No phone

Status: Recruiting

Universitätsklinikum Essen

Essen, North Rhine-Westphalia, Germany

No email / No phone

Status: Recruiting

Humanitas San Pio X

Milan, Italy

No email / No phone

Status: Recruiting

IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale

Naples, 80131, Italy

No email / No phone

Status: Recruiting

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, Italy

No email / No phone

Status: Recruiting

Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena

Rome, Lazio, Italy

No email / No phone

Status: Recruiting

ASST Grande Ospedale Metropolitano Niguarda

Milan, Lombardy, Italy

No email / No phone

Status: Recruiting

Fondazione IRCCS Istituto Nazionale Dei Tumori

Milan, Lombardy, Italy

No email / No phone

Status: Recruiting

Istituto Clinico Humanitas

Rozzano, Lombardy, Italy

No email / No phone

Status: Recruiting

Istituto Europeo Di Oncologia

Milan, Lombardy, Italy

No email / No phone

Status: Recruiting

Fondazione del Piemonte per l'Oncologia (IRCCS)

Candiolo, Torino, Italy

No email / No phone

Status: Recruiting

National Cancer Center of Singapore

Singapore, 168582, Singapore

No email / No phone

Status: Recruiting

National University Hospital

Kent Ridge, Singapore

No email / No phone

Status: Recruiting

Asan Medical Center

Seoul, South Korea

No email / No phone

Status: Recruiting

National Cancer Center

Seoul, South Korea

No email / No phone

Status: Recruiting

Samsung Medical Center

Seoul, South Korea

No email / No phone

Status: Recruiting

Seoul University Hospital

Seoul, South Korea

No email / No phone

Status: Recruiting

Severance Hospital Yonsei University

Seoul, South Korea

No email / No phone

Status: Recruiting

Hospital Clinico Universitario de Valencia

Valencia, Spain

No email / No phone

Status: Recruiting

Hospital Universitario 12 de Octubre

Madrid, 28041, Spain

No email / No phone

Status: Recruiting

Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON

Barcelona, Spain

No email / No phone

Status: Recruiting

NEXT Oncology-Hospital Quironsalud Barcelona

Barcelona, Spain

No email / No phone

Status: Recruiting

START Rioja

Rioja, Spain

No email / No phone

Status: Recruiting

START MADRID_Hospital Universitario Fundacion Jimenez Diaz

Madrid, Madrid, Spain

No email / No phone

Status: Recruiting

START MADRID_Hospital Universitario HM Sanchinarro - CIOCC

Madrid, Madrid, Spain

No email / No phone

Status: Recruiting

Sarah Cannon Research Institute UK

London, Middlesex, United Kingdom

No email / No phone

Status: Recruiting

Freeman Hospital

Newcastle upon Tyne, Tyne and Wear, United Kingdom

No email / No phone

Status: Recruiting

UCLA Jonsson Comprehensive Cancer Center

Los Angeles, California, 90024, United States

No email / No phone

Status: Recruiting

USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

No email / No phone

Status: Recruiting

University of California Irvine Chao Family Comprehensive Cancer Center

Irvine, California, 92868, United States

No email / No phone

Status: Recruiting

Rocky Mountain Cancer Center

Denver, Colorado, 80218, United States

No email / No phone

Status: Recruiting

Yale Cancer Center

New Haven, Connecticut, 06519, United States

No email / No phone

Status: Recruiting

Medical Oncology Hematology Consultants

Newark, Delaware, 19713, United States

No email / No phone

Status: Recruiting

Florida Cancer Specialists South

Port Charlotte, Florida, 33980, United States

No email / No phone

Status: Recruiting

University of Miami - Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States

No email / No phone

Status: Recruiting

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Recruiting

Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

No email / No phone

Status: Recruiting

Memorial Sloan Kettering

New York, New York, 10065, United States

No email / No phone

Status: Recruiting

Duke University

Durham, North Carolina, 27705, United States

No email / No phone

Status: Recruiting

The Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, 44195, United States

No email / No phone

Status: Recruiting

University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States

No email / No phone

Status: Recruiting

Oregon Health & Science University (OHSU)

Portland, Oregon, 97210, United States

No email / No phone

Status: Recruiting

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

No email / No phone

Status: Recruiting

WellSpan York Cancer Center

York, Pennsylvania, 17403, United States

No email / No phone

Status: Recruiting

Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Recruiting

New Experimental Therapeutics - NEXT Oncology

Austin, Texas, 78705, United States

No email / No phone

Status: Recruiting

New Experimental Therapeutics of San Antonio - NEXT Oncology

San Antonio, Texas, 78229, United States

No email / No phone

Status: Recruiting

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

UT Southwest Simmons Cancer Center

Dallas, Texas, 75390, United States

No email / No phone

Status: Recruiting

Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States

No email / No phone

Status: Recruiting

University of Washington, Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States

No email / No phone

Status: Recruiting

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53705, United States

No email / No phone

Status: Recruiting

University of San Diego Moores Cancer Center

La Jolla, California, 92093, United States

No email / No phone

Status: Not yet recruiting

Advent Health

Orlando, Florida, 32803, United States

No email / No phone

Status: Not yet recruiting

Columbia University

New York, New York, 10032, United States

No email / No phone

Status: Not yet recruiting

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

No email / No phone

Status: Not yet recruiting

UTSW - Moody Outpatient Center - Parkland Health

Dallas, Texas, 75235, United States

No email / No phone

Status: Not yet recruiting

Universitätsklinikum Frankfurt

Frankfurt am Main, Hesse, Germany

No email / No phone

Status: Withdrawn

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

No email / No phone

Status: TERMINATED

Back to trials list